Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
Seagen Inc.
Eli Lilly and Company
M.D. Anderson Cancer Center
Sun Yat-sen University
GOG Foundation
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Genmab
Eisai Inc.
University of Colorado, Denver
Institute of Cancer Research, United Kingdom
Duke University
AbbVie
AstraZeneca